While rare, we noticed clinically significant mutations in CDKN2A, which belongs to the cell cycle pathway, in the HER2+ subtype of breast cancer (P < 0.05), indicating the potential benefit of CDK4/6 inhibitors. Here, CDK4 is linked to breast carcinoma.